Blueprint Medicines — Investor Presentation (April 2017)
31 slides from Blueprint Medicines's investor presentation, Apr 5, 2017
Slide 1: A Blueprint for a Healthier Tomorrow
A Blueprint for a Healthier Tomorrow April 5, 2017
Slide 2: Forward-looking statements
Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project
Slide 3: A blueprint for a healthier tomorrow
A blueprint for a healthier tomorrow 3 Proprietary compound library combined with genomics expertise Exquisitely targeted to molecular drivers of disease Rapid path from bench to clinical proof-of-concept Culture of urgency to develop medicines for underserved patients Targeted kinase medicines for
Slide 4: A new way of looking at kinase medicines
A new way of looking at kinase medicines 4 BLU-554 Nexavar Sutent BLU-285 We aim to design and develop highly targeted kinase medicines with improved potency, less off-target activity, and a high probability of clinical success Kinome illustration reproduced courtesy of CSTI (cellsignal.com). The fo
Slide 5: 2017: Blueprint Medicines' vision becoming realized
2017: Blueprint Medicines’ vision becoming realized DATA MATURING AND EXPANDING DEVELOPMENT BLU-285: plan to present updated data in advanced GIST and SM, initiate new studies BLU-554: plan to present updated data in advanced HCC ESTABLISH REGISTRATION PATHWAY Interactions with global regulatory aut
Slide 6: Robust pipeline of diverse clinical-stage assets
Robust pipeline of diverse clinical-stage assets FLC, Fibrolamellar carcinoma; GIST, advanced gastrointestinal stromal tumors; NSCLC, non-small cell lung cancer. All Phase 1 studies are in advanced disease. 6 compound Discovery Preclinical Clinical Commercial rights BLU-285 Inhibitor of PDGFRα D842V
Slide 7: BLU-285 Phase 1 Study in Advanced GIST
BLU-285 Phase 1 Study in Advanced Gastrointestinal Stromal Tumors (GIST)
Slide 8: GIST is a rare sarcoma of the digestive tract
2 GIST is a rare sarcoma of the digestive tract 1 PDGFRα-driven GIST: Overall survival is ~15 months KIT-driven GIST: Overall survival is ~5 years No current therapy addresses PDGFRα and KIT Exon 17 mutations BLU-285 is a highly selective inhibitor of PDGFRα and KIT mutations 3 8 4 PDGFRα-driven GIS
Slide 9: Proof-of-concept established for BLU-285 in advanced GIST
Proof-of-concept established for BLU-285 in phase 1 study in advanced GIST Part 1: Dose escalation Complete Part 2: Dose expansion Enrolling 9 PDGFRα D842-mutant GIST, N=50 KIT-driven GIST, N=50 3 + 3 escalation with enrichment 400 mg QD Design couples transformative inhibitor with patient selection
Slide 10: Proof-of-concept established for BLU-285 in PDGFR-driven GIST
Proof-of-concept established for BLU-285 in PDGFR-driven GIST The values above/below the bars denote the dose level (mg) QD received by each patient. PD, progressive disease; PR, partial response; SD, stable disease. Data previously presented in December 2016 at the EORTC-NCI-AACR Molecular Targets
Slide 11: BLU-285 shows anti-tumor activity in KIT-driven GIST at higher doses
BLU-285 shows anti-tumor activity in KIT-driven GIST at higher doses The values above/below the bars denote the initial dose level (mg) QD received by each patient. Data previously presented in December 2016 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. Data cutoff: Nove
Slide 12: BLU-285 preliminary safety data in advanced GIST
BLU-285 preliminary safety data in advanced GIST No DLTs or treatment-related Grade 4 – 5 AEs No patient discontinued BLU-285 due to treatment-related toxicity 11 (31%) patients had Grade 3 or higher AEs; of these, 3 were considered treatment-related: 1 patient with Grade 3 nausea and vomiting 1 pat
Slide 13: BLU-285 Phase 1 study in Advanced Systemic Mastocytosis
BLU-285 Phase 1 study in Advanced Systemic Mastocytosis (SM)
Slide 14: Advanced SM is a rare and severe disease that shortens life expectancy
2 1 Advanced SM is a rare and severe disease that shortens life expectancy Prognosis is poor with ~3-5 years overall survival with current treatments focused on symptomatic relief KIT D816V mutation is a key driver in ~90-95% of patients1 3 14 4 Advanced SM (including smoldering) = ~4,400 patients2
Slide 15: Ongoing phase 1 study of BLU-285 in advanced systemic mastocytosis
Ongoing phase 1 study of BLU-285 in advanced systemic mastocytosis Part 1: Dose escalation Enrolling Part 2: Dose expansion Planned 15 3 + 3 escalation Design enables evaluation of BLU-285 activity across spectrum of advanced disease Part 1: MTD and RP2D, pharmacokinetics, initial assessments of cli
Slide 16: Encouraging early clinical activity with objective decreases in mast cell burden
Encouraging early clinical activity with objective decreases in mast cell burden 16 Decreased bone marrow mast cells in 6 of 8 patients Decreased serum tryptase in 10 of 12 patients The values above/below the bars denote the dose level (mg) QD received by each patient. Data previously presented in D
Slide 17: BLU-285 preliminary safety data in advanced SM
BLU-285 preliminary safety data in advanced SM No treatment-related Grade 4 – 5 AEs MTD not yet reached No patient discontinued BLU-285 due to treatment-related toxicity No dose reductions required for toxicity 1 DLT: grade 3 alkaline phosphatase elevation 2 patients had grade 3 AEs considered treat
Slide 18: BLU-554 Phase 1 Study in Advanced Hepatocellular Carcinoma
BLU-554 Phase 1 Study in Advanced Hepatocellular Carcinoma (HCC)
Slide 19: Abnormally activated FGFR4 pathway in ~30% of patients enables biomarker driven patient selection
2 1 Abnormally activated FGFR4 pathway in ~30% of patients enables biomarker driven patient selection 3 BLU-554 in hepatocellular carcinoma 19 4 BLU-554 is a selective inhibitor of FGFR4 with encouraging early single agent activity in heavily pre-treated patients in ongoing Phase 1 study 5 1L with F
Slide 20: Ongoing phase 1 study of BLU-554 in advanced hepatocellular carcinoma
Ongoing phase 1 study of BLU-554 in advanced hepatocellular carcinoma Part 1: Dose escalation Complete Part 2: Dose expansion Enrolling 20 3 + 3 escalation with enrichment Target study population includes heavily pretreated patients with a typically poor prognosis Part 1: MTD and RP2D, pharmacodynam
Slide 21: Proof-of-concept established for BLU-554 in advanced HCC
Proof-of-concept established for BLU-554 in advanced HCC 21 IHC, immunohistochemistry; PD, progressive disease; PR, partial response; SD, stable disease. Data previously presented in November 2016 at the EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium. Data cutoff: November 7, 201
Slide 22: BLU-554 preliminary safety data in advanced HCC
BLU-554 preliminary safety data in advanced HCC Adverse Events Occurring in >15% of Patients AE Category # (%) Any Grade Grade 3 or Higher Diarrhea 18 (72) 2 (8) Nausea 11 (44) 0 Abdominal pain 10 (40) 3 (12) Vomiting 10 (40) 0 Fatigue 9 (36) 2 (8) ALT increased 8 (32) 3 (12) AST increased 7 (28) 4
Slide 23: BLU-667
= jo} = 2 cS = Ee lu a BLU-667
Slide 24: BLU-667 is designed as a targeted inhibitor to achieve better RET inhibition
BLU-667 is designed as a targeted inhibitor to achieve better RET inhibition ACTIVATING RET KINASE FUSIONS AND MUTATIONS ARE IMPORTANT DISEASE DRIVERS IN A VARIETY OF CANCERS Estimate ~10,000 patients with RET-driven NSCLC and ~600 patients with RET-driven medullary thyroid cancer in major markets*
Slide 25: BLU-667 in RET-driven NSCLC, MTC and other advanced solid tumors
BLU-667 in RET-driven NSCLC, MTC and other advanced solid tumors Part 1: Dose escalation Enrolling Part 2: Dose expansion Planned 25 Escalation Phase 1 study initiated and first patient enrolled Part 1: MTD and RP2D, anti-tumor activity, pharmacokinetics, blood calcitonin (MTC) Part 2: Response rate
Slide 26: <= [S) <= Se (ae (ey,
<= [S) <= Se (ae (ey,
Slide 27: Developing first PRKACA-targeted inhibitor for treatment of Fibrolamellar Carcinoma
Developing first PRKACA-targeted inhibitor for treatment of Fibrolamellar Carcinoma FLC is a rare and distinct subtype of liver cancer in young adults with high medical need and no approved therapies to date Often associated with poor prognosis (5-year OS rate is 30-40%) Patient population estimated
Slide 28: Cash to fund operating expenses and capital expenditures into 2H 2019
Cash to fund operating expenses and capital expenditures into 2H 2019* 28 SHARES OUTSTANDING as of 12/31/16 33.1 million (basic) 35.7 million (fully diluted) OUTSTANDING DEBT as of 12/31/16 $4.1 million CASH, CASH EQUIVALENTS AND INVESTMENTS as of 12/31/16 $268.2 million * Cash guidance gives effect
Slide 29: Potential 2017 milestones
Potential 2017 milestones 29 Program Milestone BLU-285 GIST Update data from dose escalation in PDGFRα-driven advanced GIST Update data from dose escalation in KIT-driven advanced GIST Initiate expansion stage of Phase 1 study* Explore expedited clinical development pathways with regulatory authorit
Slide 30: A blueprint for a healthier tomorrow
A blueprint for a healthier tomorrow Proprietary discovery platform for highly selective and potent kinase drug candidates Strategy focused on genomically defined cancers and rare diseases Proof-of-concept demonstrated in 4 patient populations in 3 diseases with 2 candidates 3 wholly owned candidate
Slide 31: Thank you
Thank you 31
Blueprint Medicines — Investor Presentation (April 2017) on 6ix